Mel Mann: Beating Leukemia’s Odds

[audio mp3="https://pdcn.co/e/rss.art19.com/episodes/4ffb866c-0fb4-487d-9345-568d22b38130.mp3?rss_browser=BAhJIgljdXJsBjoGRVQ%3D--435795d5c850773aaa4739d968bd77a1dfd6f301"][/audio] Mel Mann: Beating Leukemia’s Odds

On the show today I speak with Mel Mann, the longest living person who participated in the clinical trial for Gleevec. When Mel Mann was diagnosed with chronic myeloid leukemia at age 37 in 1995, he was told he had three years to live. But he’s here some 26 years later and still going strong. Mel served as a major in the U.S. Army.  He kickstarted blood marrow drives all across the country. He started running marathons to raise money for cancer research. He went back to school to become a high school English teacher. And now Mel serves as a cancer advocate and patient activist. He's here to talk about his epic journey.


See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kenny Kane

Kenny Kane is an entrepreneur, writer, and nonprofit innovator with 15+ years of experience leading organizations at the intersection of business, technology, and social impact. He is the CEO of Firmspace, CEO of the Testicular Cancer Foundation, and CTO/co-founder of Gryt Health.

A co-founder of Stupid Cancer, Kenny has built national awareness campaigns and scaled teams across nonprofits, health tech, and real estate. As an author, he writes about leadership, resilience, and building mission-driven organizations.

Previous
Previous

Vax On: Do It Yourself

Next
Next

Vax On: Thanks for Mutton